NASDAQ: OGIOrganigram Global Inc Stock
$1.03+0.07 (+7.29%)
Updated Jun 26, 2026
OGI Price
$1.03
Fair Value Price
N/A
Market Cap
$140.56M
52 Week Low
$0.92
52 Week High
$2.24
P/E
-6.82x
P/B
0.51x
P/S
0.91x
PEG
N/A
Dividend Yield
N/A
Revenue
$201.61M
Earnings
-$18.27M
Gross Margin
35.6%
Operating Margin
-14.18%
Profit Margin
-9.2%
Debt to Equity
0.4
Operating Cash Flow
-$7M
Beta
1.5
Next Earnings
Aug 12, 2026
Ex-Dividend
N/A
Next Dividend
N/A
OGI Overview
Organigram Global Inc., primarily operating through its subsidiary Organigram Holdings Inc., is a Canadian enterprise specializing in the cultivation, production, and distribution of cannabis and related products. The company serves the medical cannabis market by offering products such as cannabis flowers, oils, and vaporizing devices to both civilian patients and military veterans. For adult recreational consumers, Organigram provides a diverse range of cannabis products, including edibles and concentrates, under popular brands like Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour. Additionally, the company acts as a wholesale supplier, distributing cannabis plant cuttings, dried flowers, proprietary blends, pre-rolled products, and various cannabis derivatives to retailers and other wholesalers within the adult-use recreational sector. Customers can purchase Organigram's offerings through its online platform or via telephone orders. Established in 2013, the company's corporate headquarters are located in Moncton, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine OGI's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Pharmaceutical
Industry Rating
B
OGI
Ranked#44 of 50
Ranked#44 of 50
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $168.52 | A | |
| $41.83 | A | |
| $84.50 | A |
Be the first to know about important OGI news, forecast changes, insider trades & much more!
OGI News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how OGI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
OGI is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
OGI is good value based on its book value relative to its share price (0.51x), compared to the US Drug Manufacturers - Specialty & Generic industry average (1.55x)
P/B vs Industry Valuation
OGI is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more OGI due diligence checks available for Premium users.
Valuation
OGI price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-6.82x
Industry
-4.67x
Market
12.39x
OGI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.51x
Industry
1.55x
OGI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
OGI's financial health
Profit margin
Revenue
$43.3M
Net Income
-$667.4k
Profit Margin
-1.5%
OGI's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
OGI's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$377.8M
Liabilities
$108.3M
Debt to equity
0.4
OGI's short-term assets ($183.89M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
OGI's short-term assets ($183.89M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
OGI's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
OGI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.9M
Investing
-$1.0M
Financing
-$326.8k
OGI's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
OGI vs Pharmaceutical Stocks
Organigram Global Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.